Currently, there is an ongoing observational clinical trial to identify and monitor the resistance to first-line breast cancer treatment with CDK4/6 inhibitors in combination with aromatase inhibitors (NCT04660435, TRIESIAS, Fondazione Sandro Pitigliani). Here, CYP19A1 is linked to breast carcinoma.